IHCP bulletin

INDIANA HEALTH COVERAGE PROGRAMS

BT201634 JUNE 28, 2016

Pharmacy update approved by Drug Utilization Review Board June 2016

The Indiana Health Coverage Programs (IHCP) announces changes to prior authorization (PA) criteria, enhancements to its SilentAuth automated PA system, updates to the mental health utilization edits, changes to the Preferred Drug List (PDL) and Over-the-Counter (OTC) Drug Formulary, and the addition of a Pharmacy Supplements Formulary as approved by the Drug Utilization Review (DUR) Board at its June 17, 2016, meeting. These changes apply to the fee-forservice (FFS) pharmacy benefit.

PA changes

PA criteria for Fentanyl, Hepatitis C Agents, and Egrifta were established and approved by the DUR Board. The PA exemption policy for buprenorphine and buprenorphine/naloxone "gold card" status was updated to remove the eligibility requirement of licensure in psychiatry. The policy update requires qualified prescribers to have a license to practice medicine in the state of Indiana, be in good standing with the Indiana Professional Licensing Agency (IPLA) and Indiana Family and Social Services Administration (FSSA), and have a certification in addiction medicine or addiction psychiatry. These PA changes will be effective for PA requests submitted on or after August 1, 2016. The PA criteria are posted on the *Pharmacy Prior Authorization Criteria and Forms* page under the <u>Pharmacy Services</u> quick link at indianamedicaid.com.

SilentAuth PA enhancement

The IHCP has enhanced its automated PA system to update the criteria for the Duplicate Stimulant, Duplicate Antipsychotic, Opiate Overutilization, and Targeted Immunomodulators prior authorizations. The goal is to ensure appropriate utilization for IHCP members. These enhancements will be implemented in the IHCP pharmacy claims processing system for claims with dates of service (DOS) on or after August 1, 2016.

Mental health utilization edits

Utilization edits for mental health medications are reviewed quarterly by the Mental Health Quality Advisory Committee (MHQAC). The DUR Board approved updates to the utilization edits, as recommended by the MHQAC and listed in Table 1. These updates are effective for DOS on or after August 1, 2016.

Table 1 – Updates to utilization edits effective for DOS on or after August 1, 2016

| Name and strength of medication | Utilization edit |
|-----------------------------------|------------------|
| Dyanavel XR 2.5 mg/ml suspension | 8 ml/day |
| Escitalopram (Lexapro) 20 mg tabs | 1.5/day |

Table 1 – Updates to utilization edits effective for DOS on or after August 1, 2016 (Continued)

| Name and strength of medication | Utilization edit |
|---------------------------------|------------------|
| Molindone 5 mg tabs | 4/day |
| Molindone 10 mg tabs | 4/day |
| Molindone 25 mg tabs | 9/day |
| Namenda XR 7 mg caps | 1/day |
| Namenda XR 14 mg caps | 1/day |
| Namenda XR 21 mg caps | 1/day |
| Namenda XR 28 mg caps | 1/day |
| Namenda XR Titration Pak | 1 Pak/28 days |
| Quillichew ER 20 mg chew tabs | 1/day |
| Quillichew ER 30 mg chew tabs | 2/day |
| Quillichew ER 40 mg chew tabs | 1/day |
| Vraylar Therapy Pack | 1 pack/28 days |

Changes to the PDL and OTC Drug Formulary

Changes to the PDL and OTC Drug Formulary were made at the June 17, 2016, DUR Board meeting. See Table 2 for a summary of PDL changes and <u>Table 3</u> for a summary of OTC Drug Formulary changes. Changes are effective for DOS on or after August 1, 2016, unless otherwise noted.

Table 2 – Approved changes to the PDL effective for DOS on or after August 1, 2016

| Drug Class | Drug | PDL Status |
|--|--------------------|--|
| Agents for the Treatment of Opiate Addiction | Evzio | Nonpreferred |
| of Opiate Addiction | Narcan Nasal | Preferred |
| | Naloxone injection | Preferred |
| Narcotics | Belbuca | Nonpreferred; maintain PA criteria |
| | Lazanda | Nonpreferred; age limit – 18 years and older; add to fentanyl PA criteria |
| | Methadone | Nonpreferred (previously preferred); add to nonpreferred long-acting opiate SilentAuth PA criteria |
| | Kadian | Nonpreferred (previously preferred); add to nonpreferred long-acting opiate SilentAuth PA criteria |
| | Xtampza ER | Nonpreferred; quantity limit – 2 capsules/day; add to nonpreferred long-acting opiate SilentAuth PA criteria |

Table 2 – Approved changes to the PDL effective for DOS on or after August 1, 2016 (Continued)

| Drug Class | Drug | PDL Status |
|---|--|---|
| Antidiabetic Agents (oral) | Nesina | Preferred (previously nonpreferred) |
| | Oseni | Preferred (previously nonpreferred) |
| | Kazano | Preferred (previously nonpreferred) |
| | alogliptin | Nonpreferred |
| | alogliptin/pioglitazone | Nonpreferred |
| | alogliptin/metformin | Nonpreferred |
| | | OptumRx may exchange preferred status of Nesina, Oseni, and Kazano with preference for alogliptin, alogliptin/pioglitazone, and alogliptin/metformin on PDL if financially advantageous |
| Insulins – Long Acting | Tresiba Flex | Preferred; step therapy – trial of Lantus or Levemir for 90 of the past 120 days |
| Estrogen, Progesterone, SERMs, or Combinations | Depo-Provera contraceptive 150 mg/mL suspension for injection | Maintain as nonpreferred; add quantity limit for females – 1 mL/84 days |
| | medroxyprogesterone contraceptive 150 mg/mL suspension for injection | Maintain as preferred; add quantity limit for females – 1 mL/84 days |
| Vitamins | | Remove Vitamins drug class from the PDL |
| Laxatives and Cathartics | Linzess | Preferred (previously nonpreferred); maintain step therapy – requires trial of lactulose, sorbitol, or polyethylene glycol within past 90 days |
| Proton Pump Inhibitors | Zegerid Powder | Nonpreferred; age limit – 12 years and younger; add step therapy – must try Nexium packets and Protonix packets for a total of 4 weeks, unless patient is intolerant to these agents |
| Direct Thrombin Inhibitors | Pradaxa | Maintain as preferred; remove step therapy |
| Targeted | Taltz | Nonpreferred |
| Immunomodulators | Xeljanz XR | Nonpreferred |
| | Inflectra | Nonpreferred |
| | Kineret | Preferred (previously nonpreferred) |
| Topical Immunomodulators | Enstilar | Nonpreferred |
| Hepatitis C Agents | Zepatier | Preferred (previously nonpreferred); maintain PA criteria |

Table 3 – OTC Drug Formulary changes effective for DOS on or after August 1, 2016

| Drug Class | Drug | OTC Drug Formulary Status/Criteria |
|-------------------------|--|---|
| Analgesics | Acetaminophen 100 mg/mL solution drops | Not covered |
| | Acetaminophen 160/5 mL Elixir | Not covered |
| Antacids | Aluminum hydroxide gel concentrate | Not covered |
| | Magnesium hydroxide/Aluminum hydroxide | Not covered |
| Calcium Supplements | Calcium 500 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Calcium carbonate 1.25 gm tablet chew | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Calcium carbonate/Vitamin D | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| Compounding Agents | Aquaphor ointment | Remove from OTC Drug Formulary |
| | Avobenzone/Octocrylene lotion | Remove from OTC Drug Formulary |
| | Dakin's solutions | Remove from OTC Drug Formulary |
| | Eucerin cream | Remove from OTC Drug Formulary |
| | Glycerin liquid | Remove from OTC Drug Formulary |
| | Glycerin/Dimethicone/Shea tree/ Stearyl Alcohol cream | Remove from OTC Drug Formulary |
| | Glycerin/Dimethicone/Urea/ Petrolatum/Cetyl Al lotion | Remove from OTC Drug Formulary |
| | Glycerin/Lanolin/Mineral oil lotion | Remove from OTC Drug Formulary |
| | Lanolin/Mineral oil lotion | Remove from OTC Drug Formulary |
| | Lozibase | Remove from OTC Drug Formulary |
| | Menthol/Colloidal oatmeal lotion | Remove from OTC Drug Formulary |
| | Mineral oil/Hydrophilic petrolatum ointment | Remove from OTC Drug Formulary |
| | Starch oral thickening powder/ packets | Remove from OTC Drug Formulary |
| | Suspendol-S liquid | Remove from OTC Drug Formulary |
| | Vitamin E acetate/Glycerin/ Dimethicone/Water lotion | Remove from OTC Drug Formulary |
| Cough and Cold Products | Gauifenesin/D-methorphan capsule | Not covered |
| | Gauifenesin/Pseudoephedrine syrup | Not covered |
| Emetics | Ipecac syrup | Not covered |
| Glucose/Dextrose | | Remove Glucose/Dextrose class from OTO Drug Formulary; add as Carbohydrate clas to Pharmacy Supplements Formulary |

Table 3 – OTC Drug Formulary changes effective for DOS on or after August 1, 2016 (Continued)

| Drug Class | Drug | OTC Drug Formulary Status/Criteria |
|--------------------|-------------------------------------|--|
| H2 Antagonists | Nizatidine 75 mg tablet | Not covered |
| Iron Products | | Remove Iron Products class from OTC Drug Formulary; add as Iron class to Pharmacy Supplements Formulary |
| Magnesium | | Remove Magnesium class from OTC Drug Formulary; add as Magnesium class to Pharmacy Supplements Formulary |
| Multivitamins | | Remove Multivitamins class from OTC Drug Formulary; add as Multivitamins class to Pharmacy Supplements Formulary |
| Niacin | | Remove Niacin class from OTC Drug Formulary; add as Niacin class to Pharmacy Supplements Formulary |
| Sorbitol | | Remove Sorbitol class from OTC Drug Formulary; add Sorbitol 70% solution to Miscellaneous class on Pharmacy Supplements Formulary |
| Topical Products | Diphenhydramine HCl 2% cream | Not covered |
| | Pyrethrin Spray | Not covered |
| Urinary Analgesics | Phenazopyridine 95 mg tablet | Not covered |
| Vitamins | Aqueous vitamin E oral formulations | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Ascorbic acid 250 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Ascorbic acid 500 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Ascorbic acid 1,000 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Ascorbic acid 1,500 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Ascorbic acid 500 mg/5 mL syrup | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Biotin 5 mg capsule | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Pyridoxine HCl 50 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Pyridoxine HCl 100 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Pyridoxine HCl 250 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Pyridoxine HCl 500 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |

Table 3 – OTC Drug Formulary changes effective for DOS on or after August 1, 2016 (Continued)

| Drug Class | Drug | OTC Drug Formulary Status/Criteria |
|----------------------|--|--|
| Vitamins (continued) | Riboflavin 50 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Riboflavin 100 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Thiamine 50 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Thiamine 100 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Thiamine 250 mg tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin A 10,000 IU capsule/tablet | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin B complex with/without minerals liquid | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin D 400 IU softgel/chew/tab | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin D 1,000 IU softgel/chew/ tab | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin D 400 and 8,000 units/mL drops | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin E 100 IU capsule | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin E 200 IU capsule | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin E 400 IU capsule | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| | Vitamin E 400 IU liquid | Remove from OTC Drug Formulary; add to Pharmacy Supplements Formulary |
| Zinc | | Remove Zinc class from OTC Drug Formulary; add as Zinc class to Pharmacy Supplements Formulary |

Pharmacy Supplements Formulary

The Pharmacy Supplements Formulary was established at the June 17, 2016, DUR Board meeting. See <u>Table 4</u> for the list of products included on the formulary. The formulary is effective for DOS on or after August 1, 2016, unless otherwise noted.

Table 4 – Pharmacy Supplements Formulary effective for DOS on or after August 1, 2016

| Product Class | Product | Pharmacy Supplements Formulary Status/Criteria |
|---------------|--|--|
| Amino Acids | Arginine 500 mg capsule | Covered |
| | Arginine 600 mg capsule | Covered |
| | Arginine HCl (bulk) | Covered |
| | Arginine HCl oral powder | Covered |
| | Arginine powder | Covered |
| | Arginine 500 mg tablet | Covered |
| | Arginine 1,000 mg tablet | Covered |
| Calcium | Calcium 500 mg tablet | Covered |
| | Calcium carbonate 1.25 gm tab chew | Covered |
| | Calcium carbonate 500 mg tablet | Covered |
| | Calcium carbonate 1.25 gm tablet | Covered |
| | Calcium carbonate liquid 1.25 gm/5 mL | Covered |
| | Calcium carbonate/Vitamin D | Covered |
| Carbohydrate | Dextrose 40% gel | Covered |
| | Dextrose 4 gm tab chew | Covered |
| | Dextrose 5 gm tab chew | Covered |
| Iron | Ferrous sulfate 220 mg/5 mL elixir | Covered |
| | Ferrous sulfate 220 mg/5 mL liquid | Covered |
| | Ferrous sulfate 325 mg tablet | Covered |
| | Ferrous sulfate 325 mg tablet EC | Covered |
| | Ferrous sulfate 75 mg/mL drops | Covered; age – under 18 years |
| | Novaferrum pediatric drops 15 mg/mL | Covered; age – under 18 years |
| | Polysaccharide iron 150 mg capsule/caplet/tablet | Covered |
| Magnesium | Magnesium 64 mg tablet ER | Covered |
| | Magnesium oxide 400 mg tablet | Covered |

Table 4 – Pharmacy Supplements Formulary effective for DOS on or after August 1, 2016

| Product Class | Product | Pharmacy Supplements Formulary Status/Criteria |
|---------------|---|--|
| Multivitamins | Aquadek pediatric liquid | Covered; age – under 18 years |
| | Multivitamins w/o iron, with other minerals capsule | Covered; age – under 18 years |
| | Multivitamins w/o iron, with other minerals liquid | Covered; age – under 18 years |
| | Multivitamins w/o iron, with other minerals tablet | Covered; age – under 18 years |
| | Multivitamins with iron, with other minerals liquid | Covered; age – under 18 years |
| | Multivitamins with iron, with other minerals tablet | Covered; age – under 18 years |
| | Prenatal vitamins | Covered; restricted to females under 51 years of age |
| Niacin | Niacin 50 mg tablet | Covered |
| | Niacin 100 mg tablet | Covered |
| | Niacin 250 mg tablet | Covered |
| | Niacin 500 mg tablet | Covered |
| /itamins | Aqueous vitamin E oral formulations | Covered – age under 18 years |
| | Ascorbic acid 250 mg tablet | Covered – age under 18 years |
| | Ascorbic acid 500 mg tablet | Covered – age under 18 years |
| | Ascorbic acid 1,000 mg tablet | Covered – age under 18 years |
| | Ascorbic acid 1,500 mg tablet | Covered – age under 18 years |
| | Ascorbic acid 500 mg/5 mL syrup | Covered – age under 18 years |
| | Biotin 5 mg capsule | Covered – age under 18 years |
| | Magnebind 300 mg tablet | Covered |
| | Pyridoxine HCl 50 mg tablet | Covered – age under 18 years |
| | Pyridoxine HCl 100 mg tablet | Covered – age under 18 years |
| | Pyridoxine HCl 250 mg tablet | Covered – age under 18 years |
| | Pyridoxine HCl 500 mg tablet | Covered – age under 18 years |
| | Riboflavin 50 mg tablet | Covered – age under 18 years |
| | Riboflavin 100 mg tablet | Covered – age under 18 years |
| | Thiamine 50 mg tablet | Covered – age under 18 years |
| | Thiamine 100 mg tablet | Covered – age under 18 years |
| | Thiamine 250 mg tablet | Covered – age under 18 years |
| | Vitamin A 10,000 IU capsule/tablet | Covered – age under 18 years |

Table 4 – Pharmacy Supplements Formulary effective for DOS on or after August 1, 2016

| Product Class | Product | Pharmacy Supplements Formulary Status/Criteria |
|-------------------------|--|--|
| Vitamins (continued) | Vitamin B complex with/without minerals liquid | Covered |
| | Vitamin D 400 IU softgel | Covered |
| | Vitamin D 1,000 IU softgel | Covered |
| | Vitamin D 400 IU tab chew | Covered |
| | Vitamin D 1,000 IU tab chew | Covered – age under 18 years |
| | Vitamin D 400 IU tablet | Covered |
| | Vitamin D 1,000 IU tablet | Covered |
| | Vitamin D 400 and 8,000 units/mL drops | Covered – age under 18 years |
| | Vitamin E 100 IU capsule | Covered – age under 18 years |
| | Vitamin E 200 IU capsule | Covered – age under 18 years |
| | Vitamin E 400 IU capsule | Covered – age under 18 years |
| | Vitamin E 400 IU liquid | Covered – age under 18 years |
| Zinc | Zinc 200 mg capsule | Covered – age under 18 years |
| | Zinc lozenge | Covered – age under 18 years |
| Miscellaneous | Inositol 325 mg tablets | Covered; PA required |
| | Inositol 500 mg tablets | Covered; PA required |
| | Inositol 650 mg tablets | Covered; PA required |
| | Saline nasal spray 0.65% | Covered |
| | Sodium chloride neb solution 0.9% | Covered |
| | Sodium chloride neb solution 3% | Covered |
| | Sodium chloride neb solution 7% | Covered |
| | Sorbitol 70% solution | Covered |

The PDL, OTC Drug Formulary, Pharmacy Supplements Formulary, SilentAuth criteria, mental health drug utilization edits, and PA criteria can be accessed under the Pharmacy Services quick link at indianamedicaid.com. Notices of the DUR Board meetings and agendas are posted on the FSSA website at in.gov/fssa. Click "FSSA Calendar" on the left side of the page to access the events calendar.

Please direct FFS PA requests and questions about the FFS PDL, the FFS OTC Drug Formulary, or this bulletin to the OptumRx Clinical and Technical Help Desk by calling toll-free 1-855-577-6317. Questions regarding pharmacy benefits for members in the Healthy Indiana Plan (HIP) and Hoosier Care Connect should be referred to the managed care entity (MCE) with which the member is enrolled.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope here or on the pages of indianamedicaid.com.



COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from indianamedicaid.com.

TO PRINT

A <u>printer-friendly version</u> of this publication, in black and white and without graphics, is available for your convenience.